Literature DB >> 29080504

Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles.

Guankui Wang1, Halli Benasutti1, Jessica F Jones1, Guixin Shi2, Michael Benchimol2, Sandeep Pingle3, Santosh Kesari3, Yasan Yeh4, Li-En Hsieh4, Yu-Tsueng Liu5, Anthony Elias6, Dmitri Simberg7.   

Abstract

Circulating tumor cells (CTCs) are extremely rare cells found in blood of metastatic cancer patients. There is a need for inexpensive technologies for fast enrichment of CTCs from large blood volumes. Previous data showed that antibody-conjugated lipid shell immuno-microbubbles (MBs) bind and isolate cells from biological fluids by flotation. Here, blood-stable MBs targeted to several surface markers for isolation of breast tumor cells were developed. MBs coated with anti-human EpCAM antibodies showed efficient binding of EpCAM+ breast cancer cell lines SKBR-3, MCF-7, and MDA-MB-453, whereas anti-human EGFR MBs showed binding of EpCAMLOW/NEGATIVE cell lines MDA-MB-231 and BT-549. Multitargeted anti-human EpCAM/EGFR MBs bound all cell lines with over 95% efficiency. Highly concentrated MB-bound tumor cells were collected in a microliter volume via an inverted vacuum-assisted harvesting setup. Using anti-EpCAM and/or anti-EpCAM/EGFR MBs, an efficient (70-90%) recovery and fast (30min) isolation of the above-mentioned cells and cell clusters was achieved from 7.5mL of spiked human blood. Using anti-EpCAM MBs and anti-EpCAM/EGFR MBs, cytokeratin-positive, CD45-negative CTCs were detected in 62.5% (10/16) of patients with metastatic breast cancer and CTC clusters were detected in 41.7% (5/12) of CTC-positive samples. Moreover, in some samples MBs isolated cytokeratin positive, CD45 negative tumor-derived microparticles. None of these structures were detected in blood from non-epithelial malignancies. The fast and inexpensive multitargeted platform for batch isolation of CTCs can promote research and clinical applications involving primary tumors and metastases.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody; Breast cancer; CTC; EGFR; EpCAM; Microbubbles

Mesh:

Substances:

Year:  2017        PMID: 29080504      PMCID: PMC5726926          DOI: 10.1016/j.colsurfb.2017.10.060

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  67 in total

1.  Circulating microparticles in patients with benign and malignant ovarian tumors.

Authors:  A Rank; S Liebhardt; J Zwirner; A Burges; R Nieuwland; B Toth
Journal:  Anticancer Res       Date:  2012-05       Impact factor: 2.480

Review 2.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

3.  Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Authors:  Andrew J Armstrong; Matthew S Marengo; Sebastian Oltean; Gabor Kemeny; Rhonda L Bitting; James D Turnbull; Christina I Herold; Paul K Marcom; Daniel J George; Mariano A Garcia-Blanco
Journal:  Mol Cancer Res       Date:  2011-06-10       Impact factor: 5.852

4.  All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.

Authors:  F A W Coumans; C J M Doggen; G Attard; J S de Bono; L W M M Terstappen
Journal:  Ann Oncol       Date:  2010-02-10       Impact factor: 32.976

5.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

6.  Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.

Authors:  Min Yu; Aditya Bardia; Ben S Wittner; Shannon L Stott; Malgorzata E Smas; David T Ting; Steven J Isakoff; Jordan C Ciciliano; Marissa N Wells; Ajay M Shah; Kyle F Concannon; Maria C Donaldson; Lecia V Sequist; Elena Brachtel; Dennis Sgroi; Jose Baselga; Sridhar Ramaswamy; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Science       Date:  2013-02-01       Impact factor: 47.728

7.  Isolation of rare circulating tumour cells in cancer patients by microchip technology.

Authors:  Sunitha Nagrath; Lecia V Sequist; Shyamala Maheswaran; Daphne W Bell; Daniel Irimia; Lindsey Ulkus; Matthew R Smith; Eunice L Kwak; Subba Digumarthy; Alona Muzikansky; Paula Ryan; Ulysses J Balis; Ronald G Tompkins; Daniel A Haber; Mehmet Toner
Journal:  Nature       Date:  2007-12-20       Impact factor: 49.962

8.  Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.

Authors:  Jin Woo Choi; Jun Ki Kim; Yun Jung Yang; Pilhan Kim; Kwon-Ha Yoon; Seok Hyun Yun
Journal:  Cancer Res       Date:  2015-11-01       Impact factor: 12.701

Review 9.  Lipid monolayer collapse and microbubble stability.

Authors:  James J Kwan; Mark A Borden
Journal:  Adv Colloid Interface Sci       Date:  2012-08-21       Impact factor: 12.984

10.  EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.

Authors:  Helen Schneck; Berthold Gierke; Frauke Uppenkamp; Bianca Behrens; Dieter Niederacher; Nikolas H Stoecklein; Markus F Templin; Michael Pawlak; Tanja Fehm; Hans Neubauer
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

View more
  7 in total

Review 1.  Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.

Authors:  Xiaofen Zhang; Shaoqing Ju; Xudong Wang; Hui Cong
Journal:  Clin Exp Med       Date:  2019-06-12       Impact factor: 3.984

2.  Laboratory-Scale Production of Sterile Targeted Microbubbles.

Authors:  Guixin Shi; Yu-Tsueng Liu
Journal:  Methods Mol Biol       Date:  2022

3.  EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.

Authors:  Chaoyu Zhang; Wenjie Sheng; Marwah Al-Rawe; T M Mohiuddin; Marcus Niebert; Felix Zeppernick; Ivo Meihold-Heerlein; Ahmad Fawzi Hussain
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

4.  Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer.

Authors:  Yutong He; Jin Shi; Bernd Schmidt; Qingyi Liu; Gaofeng Shi; Xiaoli Xu; Congmin Liu; Zhaoyu Gao; Tiantian Guo; Baoen Shan
Journal:  Cancer Manag Res       Date:  2020-02-05       Impact factor: 3.989

5.  Combined Effect of Anti-SSEA4 and Anti-Globo H Antibodies on Breast Cancer Cells.

Authors:  Ruey-Herng Lee; Yu-Jen Wang; Ting-Yen Lai; Tsui-Ling Hsu; Po-Kai Chuang; Han-Chung Wu; Chi-Huey Wong
Journal:  ACS Chem Biol       Date:  2021-08-09       Impact factor: 4.634

Review 6.  Nano Meets Micro-Translational Nanotechnology in Medicine: Nano-Based Applications for Early Tumor Detection and Therapy.

Authors:  Svenja Siemer; Désirée Wünsch; Aya Khamis; Qiang Lu; Arnaud Scherberich; Miriam Filippi; Marie Pierre Krafft; Jan Hagemann; Carsten Weiss; Guo-Bin Ding; Roland H Stauber; Alena Gribko
Journal:  Nanomaterials (Basel)       Date:  2020-02-22       Impact factor: 5.076

Review 7.  UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy.

Authors:  Ivan Presta; Fabiana Novellino; Annalidia Donato; Domenico La Torre; Caterina Palleria; Emilio Russo; Natalia Malara; Giuseppe Donato
Journal:  Int J Mol Sci       Date:  2020-03-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.